For the Inventor, By the Inventor

Enter assignee name

Austin, TX, United States of America

Ambion, Inc.

USPTO Granted Patents = 25

% Expired Patents = 16.0

EPO Patents = 6

Trademarks = 16

Forward Citations = 921

Loading Chart...

Loading Chart...

25 inventors (with patents filed for the assignee):

Matthew M Winkler (15 out of 21 patents)

Marianna M Goldrick (8 out of 14 patents)

Brittan L Pasloske (7 out of 21 patents)

4. Dwight B DuBois (4 out of 11 patents)

5. Susan C Milburn (3 out of 3 patents)

6. Eric S Lader (3 out of 3 patents)

7. David Allen Brown (2 out of 74 patents)

8. William Wu (2 out of 8 patents)

9. W Antoni Kudlicki (2 out of 4 patents)

10. Gary J Latham (1 out of 17 patents)

11. Richard Conrad (1 out of 23 patents)

12. George L Murphy (1 out of 6 patents)

13. Mike Byrom (1 out of 19 patents)

14. Dmitriy Ovcharenko (1 out of 17 patents)

15. Jon Kemppainen (1 out of 5 patents)

Core Competencies:

RNA Extraction

Nuclease Inhibitors

mRNA Isolation

Ribonuclease Resistance

Polynucleotide Synthesis

Electroporation

RNA Preservation

Base Pair Mismatches

Nucleic Acid Amplification

Synthetic Dnase I

Tissue Samples

RNA Transcription

25 patents: Sort by Forward Citations

1. 7250270 - Methods and compositions for preparing tissue samples for RNA extraction (2007-07-31),

2. 7163793 - Nuclease inhibitor cocktail (2007-01-16),

3. 7067298 - Compositions and methods of using a synthetic Dnase I (2006-06-27),

4. 7033749 - Ribonuclease resistant RNA preparation and utilization (2006-04-25),

5. 6994963 - Methods for recombinatorial nucleic acid synthesis (2006-02-07),

6. 6897069 - System and method for electroporating a sample (2005-05-24),

7. 6891032 - Methods and compositions for stripping nucleic acids (2005-05-10),

8. 6825340 - Methods and reagents for inactivating ribonucleases (2004-11-30),

9. 6812341 - High efficiency mRNA isolation methods and compositions (2004-11-02),

10. 6777210 - Method and reagents for inactivating ribonucleases RNase A, RNase I and RNase T1 (2004-08-17),

11. 6664379 - Nuclease inhibitor cocktail (2003-12-16),

12. 6586219 - Compositions and methods for increasing the yields of the in vitro RNA transcription and other polynucleotide synthetic reactions (2003-07-01),

13. 6586218 - Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions (2003-07-01),

14. 6528641 - Methods and reagents for preserving RNA in cell and tissue samples (2003-03-04),

15. 6365731 - Stripping nucleic acids with iodine and sodium thiosulfate (2002-04-02),

Company Overview

Ambion, Inc., based in Austin, Texas, specializes in the development and manufacturing of innovative products for molecular biology research. The company focuses on providing high-quality reagents and tools for RNA analysis, including synthesis, purification, and detection. Ambion's expertise lies in advancing the understanding of gene expression and regulation, supporting researchers in various fields such as genomics, proteomics, and diagnostics. Their commitment to scientific excellence fosters advancements in biotechnology and life sciences.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

25 Patents

#125 in Austin, TX

#778 in Texas

#13,350 in US

#25,681 in the World

Austin, TX, United States of America

Ambion, Inc.

Forward Citations = 921

25 inventors:

Matthew M Winkler (15 out of 21 patents)

Marianna M Goldrick (8 out of 14 patents)

Brittan L Pasloske (7 out of 21 patents)

4. Dwight B DuBois (4 out of 11 patents)

5. Susan C Milburn (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ambion, Inc.. Retrieved from https://idiyas.com/company/ambion

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…